Part 10/13:
Indian pharmaceutical companies, such as Zydus Cadila and Premise Biotech, are ramping up capacity to produce hundreds of millions of doses. For instance, Premise Biotech is developing its first COVID-19 vaccine, operating machinery capable of delivering 5 million doses weekly, with the aim to scale further. Their innovation involves yeast-based vaccine platforms, which promise efficiency and cost-effectiveness—offering a vaccine that could be at least 30% cheaper than existing options.